Shuang Chen

USPTO Granted Patents = 21 (Patent Applications = 9)

CIPO Patents = 7 (Patent Applications = 2)

EPO Patents = 8 (Patent Applications = 11)

Average Co-Inventor Count = 6.1

ph-index = 6

Forward Citations = 94(Granted Patents)

Company Filing History:

Abbott Laboratories Corporation

patents

Years Active: 2010-2021

Loading Chart...

21 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10954202 - Protein tyrosine phosphatase inhibitors and methods of use thereof (2021-03-23),

2. 10730873 - Salts and crystalline forms of an apoptosis-inducing agent (2020-08-04),

3. 9840502 - Salts and crystalline forms of an apoptosis-inducing agent (2017-12-12),

4. 9561181 - Crystal forms (2017-02-07),

5. 9464078 - Monohydrate of azaadamantane derivatives (2016-10-11),

6. 9359356 - Azaadamantane formate ester and process for preparing azaadamantane derivatives (2016-06-07),

7. 9321807 - Crystal forms (2016-04-26),

8. 9238649 - Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide (2016-01-19),

9. 9139536 - Anti-infective agents and uses thereof (2015-09-22),

10. 8987453 - Azaadamantane derivatives and methods of use (2015-03-24),

11. 8986740 - Anti-infective agents and uses thereof (2015-03-24),

12. 8969562 - Azaadamantane formate ester and process for preparing azaadamantane derivatives (2015-03-03),

13. 8722657 - Salts and crystalline forms of an apoptosis-inducing agent (2014-05-13),

14. 8501238 - Anti-infective agents and uses thereof (2013-08-06),

15. 8314119 - Azaadamantane derivatives and methods of use (2012-11-20),

Sure! Here's an article about inventor Shuang Chen:

Title: The Innovative Journey of Shuang Chen in Pharmaceutical Inventions

Introduction:

Shuang Chen, a prolific inventor based in Gurnee, Illinois, has made significant contributions to the field of pharmaceuticals with his groundbreaking patents and research endeavors. With a total of 21 patents to his name, Chen is recognized for his expertise in developing novel compounds and formulations for the treatment of various diseases.

Latest Patents:

Chen's latest patents include innovative inventions such as "Protein tyrosine phosphatase inhibitors and methods of use thereof" and "Salts and crystalline forms of an apoptosis-inducing agent." These patents focus on inhibiting protein tyrosine phosphatase and inducing apoptosis in diseases like cancer and metabolic disorders, showcasing Chen's commitment to advancing therapeutic interventions.

Career Highlights:

Having worked with renowned companies such as AbbVie Inc. and Abbott Laboratories Corporation, Chen has garnered extensive experience in the pharmaceutical industry. His expertise in drug development and patent applications has led to the successful commercialization of several life-changing medications.

Collaborations:

Throughout his career, Chen has collaborated with esteemed professionals in the field, including Geoff G Z Zhang and Rodger F Henry. These collaborations have not only enhanced the innovative potential of his research but have also fostered a culture of knowledge sharing and expertise exchange.

Conclusion:

In conclusion, Shuang Chen stands as a pioneering figure in the realm of pharmaceutical inventions, with a strong track record of patenting novel compounds and treatment modalities. His dedication to improving healthcare outcomes through innovation and collaboration continues to inspire future generations of inventors in the industry.

This text is generated by artificial intelligence and may not be accurate.